In a humidity-controlled weighing suite maintained at 18–25 °C and ≤40% relative humidity, the dihydrochloride salt is dispensed into nitrogen-purged, low-permeation polyethylene liners. Because the molecule is an amino acid derivative bearing a protonated amino group and two chloride counterions, bulk powder flow is affected by moisture uptake; if the measured loss on drying by USP <731> exceeds 0.5% w/w, a pre-drying step in a vacuum shelf dryer at 40 °C ± 2 °C is introduced before analytical weighout. A rotary tablet press equipped with B-tooling, a paddle feeder speed of 30–60 rpm, precompression of 2–5 kN and main compression of 8–16 kN is then used; final tablet hardness is established from disintegration and dissolution data rather than from a fixed numerical target. Content uniformity is measured by USP <905>, and dissolution is tested by USP <711> in the registered media. The chloride salt may produce a low apparent pH in a wet granulation or aqueous coating environment; therefore, direct compression is qualified only when the API concentration in the blend is low enough that a geometric dilution of 1:10 with directly compressible excipients yields an assay variance below 2% RSD across six probe locations. Tablet tooling surfaces should be electropolished 316L stainless steel or coated, because chloride ions from the dihydrochloride can accelerate pitting corrosion on unpassivated tooling during extended campaigns. If tablets show capping or lamination, dwell time is increased and turret speed reduced before any formulation change is made.

What changes when the dihydrochloride salt moves from direct compression into dosator-type capsule filling?

When the same salt is transferred to a dosator or tamping-pin capsule filler, the control focus shifts from compactibility to bed packing density, particle size distribution, and electrostatic charge. The tapped bulk density of the API-excipient blend is measured according to USP <616>, and if the Carr index exceeds 25 or the Hausner ratio exceeds 1.35, a granulation step is inserted before filling because dosator chambers cannot maintain uniform fill weight with a cohesive, poorly flowing blend. On a continuous-motion capsule filler with a powder bed depth of 20–40 mm, fill weight control is qualified at a machine speed of 60,000–120,000 capsules per hour for hard gelatin capsules; the target fill weight for low-dose API is confirmed by serial weight checks against USP <905>. Empty hard gelatin capsules are pre-conditioned to 35–45% humidity so that shell brittleness does not create splitting defects during closing. For this specific dihydrochloride salt, hygroscopicity must be managed by maintaining the powder hopper at ≤30% RH using dry compressed air; if electrostatic attraction causes the API to adhere to the hopper wall, colloidal silicon dioxide at 0.25–0.5% w/w is added in a pre-blend step rather than increasing lubricant level, because excessive magnesium stearate can delay dissolution. The filled capsule shell is then checked for moisture-related crosslinking or brittleness under accelerated storage at 40 °C/75% RH according to ICH Q1A, and dissolution is re-tested using USP <711> to confirm no change from capsule fill composition.

Fluid-bed granulation of the dihydrochloride salt is evaluated when direct compression blends fail the segregation acceptance criterion because the API has a large particle-size differential relative to direct-compression excipients. A top-spray fluid-bed granulator with a product bowl volume of 10–600 L is charged with a pre-blend of the salt, lactose monohydrate, microcrystalline cellulose, and a binder such as povidone K30; purified water or a hydroalcoholic binder solution is sprayed at a rate of 15–30 g/min per kg of dry mass until the endpoint granule moisture reaches 8–12% w/w. Because the salt has two chloride counterions, aqueous binder solutions can dissolve a portion of the API and cause recrystallization during drying; the dried granules are therefore tested by X-ray powder diffraction according to USP <941> and differential scanning calorimetry according to USP <891> to verify that no polymorphic or salt-disproportionation change has occurred. Drying is performed at an inlet air temperature of 50–60 °C and an exhaust air temperature stop of 30–35 °C; final moisture content is confirmed by loss on drying at 105 °C using USP <731>. Milled granules are sized through a 0.5–1.0 mm conical screen and blended with disintegrant and lubricant in a V-blender at 60–70% nominal volume. If the granulation endpoint is not reached within 30 min of spraying, binder viscosity is reduced by 10–20% instead of increasing spray rate, because a higher spray rate with a chloride-containing API promotes localized over-wetting and the formation of hard agglomerates that survive dry milling.

Wurster coating operations for release-controlling granules

For release-controlling granules, the Wurster insert is configured with a partition height of 10–30 mm above the distributor plate and an air distribution plate opening pattern that delivers a product bed pressure drop of 500–1000 Pa; the liquid spray nozzle is positioned inside the insert at a distance of 25–40 mm from the plate. An aqueous ethylcellulose dispersion is applied at a solids content of 15–20% w/w with a plasticizer such as dibutyl sebacate at 20–25% of polymer solids; the spray rate is set at 8–15 g/min per kg of substrate and the inlet air temperature is held at 45–55 °C while the product temperature is maintained between 30 and 35 °C. The acidic microenvironment created by the dihydrochloride salt can interact with methacrylic acid copolymer coatings, so a subcoat of hydroxypropyl methylcellulose at 3–5% w/w of granule weight is applied before enteric coating. Coating endpoint is determined by batch weight gain and is cross-checked by dissolution testing in 0.1 M HCl for 2 h followed by pH 6.8 phosphate buffer according to USP <711>. Residual solvents from the coating system are controlled by ICH Q3C and measured by gas chromatography. A Wurster run is terminated early if the outlet air humidity rises above 12 g/kg dry air, because excessive humidity causes the chloride salt to become tacky and leads to agglomerate collapse within the partition tube.

Aqueous solubility of the dihydrochloride salt is the basis for injectable formulation, but the equilibrium pH of an aqueous solution of the salt is typically acidic and must be measured before pH adjustment. A small-volume parenteral formulation is prepared by dissolving the API in Water for Injection at 15–25 °C, adding tonicity-adjusting excipients such as mannitol at 2–5% w/v or sodium chloride at 0.9% w/v, and titrating with 0.1 M sodium hydroxide or 0.1 M hydrochloric acid to the pH range established by forced-degradation and stability studies. Because the dihydrochloride salt contributes two chloride equivalents per mole, the use of sodium chloride as a tonicity agent may increase total chloride load; mannitol is preferred when chloride load is a formulation constraint. The solution is filtered through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane that has been tested for adsorption loss at a filtration rate of 0.5–2.0 L/min per 10-inch cartridge; filter flush volume is defined by sampling the first 2 L of filtrate for assay and discarding until the active concentration is within 98–102% of the pre-filtration value. The filtered solution is filled in an ISO 14644-1 Class 5 environment under unidirectional airflow according to EU GMP Annex 1. Subvisible particulate matter is controlled by USP <788>, visible particulates by USP <790>, bacterial endotoxins by USP <85>, and sterility by USP <71>. Container closure systems are selected from coated bromobutyl rubber stoppers and Type I borosilicate glass vials; extractables and leachables are evaluated by USP <1664> and elemental impurities by ICH Q3D. Published stability data for this exact configuration are limited, and therefore the assigned shelf life is derived from primary stability batches under ICH Q1A rather than transferred from another amino acid salt.

Lyophilized matrix design, collapse temperature, and container closure integrity

If lyophilization is required instead of a ready-to-use solution, the collapsed-cake failure mode controls the cycle. Freeze-drying microscopy and differential scanning calorimetry are used to determine the glass transition temperature of the maximally freeze-concentrated solute; if the collapse temperature is below −25 °C, the formulation is modified with a crystallizing bulking agent such as mannitol at 2–4% w/v or glycine at 1–2% w/v to provide a rigid cake. The filled vials are loaded onto a lyophilizer shelf pre-cooled to 5 °C, then frozen at a ramp rate of 0.5–1.0 °C/min to −45 °C, and held for 120–180 min to ensure complete solidification and to avoid collapse during primary drying. Primary drying is performed at a shelf temperature of −20 to −10 °C and a chamber pressure of 100–150 µbar for a duration determined by comparative pressure measurement; the endpoint is reached when the Pirani gauge and capacitance manometer converge within 20 µbar. Secondary drying is performed at 25–30 °C and 50–80 µbar until residual moisture in the cake is below 1.0% w/w by Karl Fischer titration according to USP <921>. The lyophilized product is sealed under vacuum or a partial nitrogen atmosphere; closure integrity is confirmed by laser-based headspace analysis or vacuum decay according to USP <1207>. Before release, reconstitution time is measured with the registered diluent, and the reconstituted injection is re-tested for particulate matter and assay. Because the dihydrochloride salt lowers the pH of the reconstituted solution, the diluent may include a buffering agent or a pH-adjusting agent; however, published data for this exact lyophilized configuration are limited, so buffer concentration is established empirically using pH stability studies at 2–8 °C and 25 °C rather than transferred from another amino acid salt. The lyophilized cake must be protected from moisture; vials are stored in low-humidity packaging with desiccant and labelled with a residual moisture specification. If freeze-dried cakes show shrinkage or loss of structural integrity during accelerated storage at 40 °C/75% RH, the cycle is re-qualified with a lower primary drying temperature and a longer secondary drying ramp.